Intranasal Influenza Vaccine in a Working Population
Open Access
- 1 April 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (7) , 974-980
- https://doi.org/10.1086/386330
Abstract
In the present study, we assessed the incidence of adverse events and influenza-like symptoms in a working population in Switzerland that was vaccinaKeywords
This publication has 19 references indexed in Scilit:
- Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in SwitzerlandNew England Journal of Medicine, 2004
- Estimating Deaths Due to Influenza and Respiratory Syncytial VirusPublished by American Medical Association (AMA) ,2003
- Influenza virus infection in infancy and early childhoodPaediatric Respiratory Reviews, 2003
- Mortality Associated With Influenza and Respiratory Syncytial Virus in the United StatesJAMA, 2003
- Influenza: vaccination and treatmentEuropean Respiratory Journal, 2001
- Safety and Immunogenicity of Intranasally Administered Inactivated Trivalent Virosome‐Formulated Influenza Vaccine ContainingEscherichia coliHeat‐Labile Toxin as a Mucosal AdjuvantThe Journal of Infectious Diseases, 2000
- Impact of Respiratory Virus Infections on Persons With Chronic Underlying ConditionsJAMA, 2000
- Update on Influenza and Rhinovirus InfectionsPublished by Springer Nature ,1999
- The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in ChildrenNew England Journal of Medicine, 1998
- Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990Epidemiology and Infection, 1996